As Fas/FasL signaling is the main mechanism of AICD, it can be concluded that ICI therapy, and CD38 upregulation after treatment, seem to be associated with the activation of AICD, which may in turn lead to the depletion of activated cytotoxic CD8+ T cells in the TME and, consequently, tumor growth. This evidence concerns the gene CD38 and neoplasm.